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Objective(s): Diversity among health care providers is felt to be an
important component in addressing health care disparities and may help
improve patient communication. Caucasian men have historically repre-
sented vascular surgery (VS). We hypothesized that the 5-year integrated VS
residency paradigm might foster increased diversity.
Table. Applicants in vascular surgery training
% Independent (52) % Integrated (05)
Year Female Cauc Black Asian
Nat
Am Other
No
resp Female Cauc Black Asian
Nat
Am Other
No
resp
2007 15.8 54.2 5.2 25.2 0.0 4.5 11.0 0 83.3 0.0 0.0 0.0 16.7 0.0
2008 18.3 60.0 6.9 23.1 0.8 2.3 6.9 16.1 41.2 5.3 28.1 0.0 13.2 12.3
2009 19.5 63.7 4.8 15.3 0.0 4.0 12.1 22.1 39.6 5.8 24.0 0.0 11.0 19.5
2010 26.3 53.8 6.7 23.5 0.0 3.4 12.6 20.3 38.9 9.7 28.3 0.9 8.3 14.0
2011 27.1 53.5 3.1 29.4 0.7 4.6 11.6 22.9 54.1 1.9 18.5 0.6 8.2 26.1
First year residents in integrated vascular
residency First year fellows in vascular surgery
# Female # Male
% Female in PGY
1 year # Female # Male
% Female in first
year fellowship
2007 0 6 0% 15 104 13%
2008 3 11 21% 16 99 14%
2009 5 17 23% 18 99 15%
2010 9 18 33% 14 109 13%
2011 17 12 59% 20 94 18%
Methods: Applicant sex and race status listed on the Electronic Resi-
dent Application System (ERAS) from 2007 to 2011 was evaluated on all
applications to integrated (5-year) VS residencies and fellowships (2 year).
Sex data were available for all of VS Accredited Council for Graduate
Medical Education (ACGME) integrated residencies and fellowships. VS
training programs were also reviewed to determine diversity of program
directors and faculty.
Results: Female applicants to VS integrated programs increased 20-
fold during the 5-year study period, from 0 (0%) in 2007 to 69 (22.9%) in
2011, compared with a 1.7-fold increase in fellowship applicants. African
American applicants to integrated programs during the study period ranged
from 0% to 9.7% and Asian applicants from 0% to 28.3% (Table). There were
no women (0%) in the 2007 integrated intern class and 17 (59%) in the 2011
postgraduate year 1 class, compared with 15 (13%) and 20 (18%), respec-
tively, in the fellowships. Of 32 integrated VS programs in 2010, three
(9.4%) program directors were women, one (3.1%) was Asian, and 22
(68.7%) were Caucasian men. Of the 101 VS fellowship program directors,
seven (6.9%) were women, six (5.9%) were Asian, and 74 (73.2%) were
Caucasian men. One or more female VSs were on staff at 20 (62.5%) of the
VS divisions that had integrated training programs.
Conclusions: Redesigning training in VS appears to appeal to women,
with less effect on race. There remains room to increase diversity among
trainees, program directors, and faculty in VS training programs.
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Objective(s): The Belgian-Italian Trial Investigating Abbott Vascular
Vascular Iliac Stents in the Treatment of TASC A, B, C and D Iliac Lesions
(BRAVISSIMO) study is a prospective, nonrandomized, multicenter trial,
conducted at 12 Belgian hospitals and 11 Italian hospitals. The objective is
to evaluate the long-term (24-month) outcome of the self-expanding nitinol
Absolute Pro (Abbott Vascular) and the balloon-expandable Omnilink Elite
(Abbott Vascular) stent in TransAtlantic InterSociety Concensus (TASC) A
and B and TASC C and D iliac lesions. A separate analysis of both patient
populations is performed.
Methods: Primary study end point is primary patency at 12 months,
defined as a target lesion without a hemodynamically significant stenosis
(50%, systolic velocity ratio 2.0) on duplex ultrasound imaging and
without target lesion revascularization (TLR) 12 months. The study
included 325 patients, of which 190 presented with TASCA or B lesions and
135 with TASC C or D lesions. Analysis is performed comparing the results
of the TASC A/B cohort with the results of the TASC C/D cohort.
Results: The study included 131 patients with TASC A, 59 with TASC
B, 54 with TASC C, and 82 with TASC D aortoiliac lesions. Demographic
data were comparable for all TASC patient groups. Of the TASC A patients,
85 received Omnilink Elite stents, 45 received Absolute Pro stents, and one
received both stents. Of the TASC B patients, 24 received Omnilink Elite
stents, 24 received Absolute Pro stents, and mixed stent use was reported in
two patients. In the TASC C group, 14 patients were treated with Onmilink
Elite, 34 with Absolute Pro, and six with both stents. Of the TASC D
patients, 29 received the Omnilink Elite, 35 received the Absolute Pro, and
18 received both. The 12-month primary patency rates were uniformly high,
without statistically significant differences among TASC groups: A, 94%; B,
96%; C, 91%; and D, 88%. Stratified by stent use, 12-month primary patency
rates were 96% for self-expanding stents, 90% for balloon-expandable stents,
and 84% for the 27 patients treated with both types (P  .03).
Conclusion: Primary endovascular treatment of symptomatic iliac
artery occlusive disease produces 12-month patency 88% irrespective of
TASC classification. On the basis of these findings, endovascular therapy
should be considered the treatment of choice for this condition; primary
aortofemoral bypass is no longer indicated for isolated iliac artery occlusive
disease.
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Objective(s):During the past decade, the treatment of popliteal aneu-
rysms has evolved at our institution from the sole operative intervention
during the initial part of the study period, to combined surgical and
endovascular treatment, and finally, to endovascular-centered management
in more recent years. Outcomes among treatment modalities for popliteal
aneurysms were assessed.
Methods: This is a retrospective review of all patients with popliteal
aneurysms treated at our institution from 2001 to 2011. Data collection
included the indication for intervention, treatment details, interventional
patency, limb salvage, perioperative outcome, and long-term survival.
Results: During this period, 88 aneurysms were treated in 72 patients.
Indications for intervention included 47 (53%)with symptomatic presentations,
and 41 (47%) were asymptomatic. Treatment included endovascular exclusion
in 24, surgical repair in 63 (14 posterior approach and 49medial approach with
bypass and exclusion), and primary amputation in one patient. Nine aneurysms
(10.2%) received catheter-directed thrombolysis (Fig). Demographics were
similar between the two treatment cohorts, except for age, with endovascular
stenting patients significantly older (76.0 vs 66.0 years, P  .002). The mean
length of stay was 3.9 vs 9.5 days (P .001), favoring endovascular treatment.
Therewere no perioperative (30-day) deaths in the endovascular group and one
death in the surgical cohort. The mean patency follow-up was 18.5 vs 28.3
months. Primary patency did not differ between endovascular and surgically
treated patients at 1 year (92.3% vs 83.3%,P .26) and3 years (61.5% vs 77.8%,
P  .89). No limbs were lost in the endovascular group during the follow-up
period of 22.4months.One late limb loss occurred in the surgical cohort (mean
follow-up, 29.2 months). The long-term survival rate was 65% in the endovas-
cular patients (mean follow up, 33.9months) and 80.8% in the surgical patients
(mean follow up, 42.9 months, P .22).
Conclusions: Endovascular treatment of popliteal aneurysms provides
similar short-term patency to that of the traditional gold standard approach
Fig.
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with surgical bypass, with shorter hospitalizations in symptomatic and
asymptomatic patients. Further long-term follow-up is required to compare
these two treatment modalities for durability to determine the optimal
popliteal aneurysm management.
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Objective(s): The goal was to create a multifactorial Disease Severity
Score (DSS) for characterization of femoropopliteal arterial lesions. By
having a greater understanding of the effect of patient comorbidities and an
in-depth method to characterize an arterial lesion, we may be able to better
compare lesions in different studies and predict which therapy is most
appropriate for each lesion undergoing an endovascular intervention (EVI).
Methods: We evaluated 44 lesion and patient characteristics in our
prospectively maintained lower extremity arterial lesion database from 2005
to 2009 to create a gradated DSS.
Results: We identified 1329 femoropopliteal lesions in 675 patients.
Statistical analysis by multivariable Cox proportional hazards model identi-
fied 16 variables that impact patency: seven lesion characteristics (Table I)
and nine patient characteristics or comorbidities (Table II). Factors with the
most impact were a chronic total occlusion (DSS 16), lesion length 100
mm (DSS 13), and no runoff vessels and stenosis of 80% to 99% (DSS 9).
The following factors were considered baseline, or score of 0: stenosis80%,
lesion length 100 mm, and three-vessel runoff. By adding these variable
scores, a DSS was created and used to predict patency of the EVI.
Conclusions: The presence of a chronic total occlusion, lesion
length 100 mm, poor runoff, and the presence of congestive heart
failure have the most dramatic effect on patency after EVI. A compre-
hensive DSS allows for the in-depth classification of lesion characteristics
and factors that predict success of EVI and can allow for comparison of
distinct lesions. Future comparisons of effectiveness of treatment modal-
ities can be possible.
Table I. Significant femoropopliteal lesion characteristics that negatively
impact patency after endovascular intervention
Factor Score HR (95% CI)
Chronic total occlusion 16 1.73 (1.28-2.33)
Stenosis 80%-90% 9 1.38 (1.06-1.78
Lesion length 100 mm 13 1.55 (1.25-1.93)
Vessel runoff
0 9 1.36 (0.95-1.96)
1 7 1.29 (0.96-1.73)
2 1 1.04 (0.77-1.40)
Lesion calcification 1 1.04 (0.82-1.31)
CI, Confidence interval; HR, hazard ratio.
Table II. Patient characteristics that impact patency after endovascular
intervention
Factor (N  16) Score Cox coefficient HR (95% CI)
CHF 8 0.274 1.32 (0.99-1.74)
Female sex 7 0.227 1.25 (0.96-1.63)
Current smoker 7 0.234 1.26 (0.80-1.99)
Former smoker 3 0.121 1.13 (0.85-1.50)
Diabetes 6 0.199 1.22 (0.94-1.58)
CAD 4 0.147 1.16 (0.88-1.53)
Renal 4 0.140 1.15 (0.85-1.55)
Age, years
50-64 6 0.195 1.22 (0.84-1.76)
65-79 2 0.075 0.93 (0.69-1.25)
CAD, Coronary artery disease; CHF, congestive heart failure; CI, confi-
dence interval; HR, hazard ratio.
Defining the Role of Endovascular Therapy in Critical Limb Ischemia
With Tissue Loss
Andrew J. Meltzer, MD, Gisberto Evangelisti, MD, Ashley Graham,
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Objective(s): We compare the utility of endovascular therapy (ET)
with bypass surgery for critical limb ischemia (CLI) with tissue loss and
identify risk factors for failure of ET.
Table.
Hazard
ratio (HR/
AOR)
95% CI for HR/
AOR P value
Overall survival
Dialysis dependence 3.0 1.1–81. .03
Angina 5.1 1.3–20.3 .02
COPD 3.8 1.8–8.3 .001
Amputation free survival
Rutherford 6 3.6 1.4–9.2 .007
COPD 3.6 1.3–9.6 .01
Limb salvage
Rutherford 6 35.1 5.4–231 .0001
Wound healing at 12 months
Diabetes 7.0 1.4–36 .02
Current smoking 5.3 1.1–26 .04
Patency loss 4.8 1.1–22 .04
Methods: A retrospective review (2004 to 2010) of patients under-
going ET for tissue loss (Rutherford class 5 and 6) provided data for
multivariate models of overall survival, amputation-free survival (AFS),
limb salvage, and wound healing. Comparisons were made with a bypass
surgery cohort matched for tissue loss.
Results: Ninety-four patients underwent ET (58% TransAtlantic
InterSociety Concensus [TASC] C/D; 44% tibial) for Rutherford 5
(88%) or Rutherford 6 (12%) CLI with tissue loss of the heel (15%),
forefoot (16%), toe(s) (43%), calf/ankle (11%), or multiple locations
(15%). Sustained limb salvage was 83%  5%. Overall survival was 44% 
7% and AFS was 40% 7% at 2 years. Predictors of failure by multivariate
models are reported in the Table. Comparison between the Rutherford 5
WRsubgroup (n  83) and an Rutherford 5 bypass cohort (n  66),
suggest equivalent limb salvage, with reduced AFS (P  .04) and a trend
toward reduced overall survival (P  .09). Early would healing was
higher after bypass: 43% vs 11% at 3 months (P  .001) and 57% vs 30%
at 6 months (P  .01).
Conclusions: Given the short life expectancy of patients with tissue
loss, ET permits sustained limb salvage in patients at high risk for bypass
(particularly Rutherford 5). However, wound healing is slow compared
with bypass and requires sustained patency.
Midterm Results of Limb Salvage and Stent Patency with Popliteal
Artery Stenting Across the Knee Joint
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Objective(s): This study evaluated the relationship of stent location on
limb salvage and stent patency in patients undergoing popliteal artery
stenting.
Methods: We performed a retrospective review of a prospectively
collected database, identifying all patients undergoing popliteal artery
stenting between September 2009 and February 2012. Patients were
divided into two groups based on the position of the distal end of the
stent in relation to the knee joint. The proximal popliteal stent group
included patients receiving a stent ending above the patella (above the
flexion point of the knee). The distal popliteal stent group included
patients receiving a stent(s) ending below the patella (in the flexion
zone). Data collected included demographics, indication for surgery,
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